Semax-5mg.png
Semax-thumbmail-1
Semax-thumbmail-2
Semax-10mg.png
Semax-5mg.png
Semax-1
Semax-2
Semax-10mg.png
Description

Semax is a synthetic heptapeptide developed at the Russian Academy of Sciences, structurally based on a fragment of adrenocorticotropic hormone (ACTH 4-7) with a C-terminal Pro-Gly-Pro extension that improves stability.

It has been investigated in research for purported nootropic and neuroprotective effects, including modulation of BDNF, dopaminergic signaling, and outcomes in experimental models of cerebral ischemia.

Clinical use is largely confined to Russia. Most peer-reviewed literature originates from Russian institutions. It is used as a research tool in studies of cognition and neuroprotection.

For research purposes only. Not for human consumption.

Key researches

Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (Dolotov OV et al., 2006)

Brain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion (Sudarkina OY et al., 2021)

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (Liu R et al., 2025)

Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Eremin KO et al., 2005)

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Glazova NY et al., 2021)

Semax

$44.00
Choose Dosage
Out of Stock